The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
Open Access
- 13 March 2012
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (8) , 1386-1394
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 32 references indexed in Scilit:
- Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian CarcinomaClinical Cancer Research, 2011
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionProceedings of the National Academy of Sciences, 2009
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Molecular Cancer Therapeutics, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K MutationsCancer Research, 2008
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-κB PathwaysThyroid®, 2008
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990